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Abstract 
Background: Early accurate diagnosis and sustainable availability of affordable medicines and diagnostic tests 
is fundamental in optimal management of asthma and chronic obstructive pulmonary disease (COPD). We 
systematically reviewed original research articles about availability and affordability of medicines and diagnostic tests 
recommended for management of asthma and COPD in sub-Saharan Africa (SSA).
Methods: We searched PubMed, Scopus and African Journal Online for original research articles conducted in SSA 
between 2000 and March 2018 containing information about availability and affordability of any recommended 
medicine and diagnostic test for asthma and COPD.
Results: The search yielded 9 eligible research articles. Availability of short-acting beta agonists (SABA), inhaled 
corticosteroids (ICS) and short acting anti-muscarinic agents (SAMA) ranged between 19.9–100%, 0–45.5% and 
0–14.3% respectively. Combination of ICS-long acting beta agonists (LABA) were available in 0–14.3% of facilities 
surveyed. There was absence of inhaled long acting anti-muscarinic agents (LAMA) and LAMA/LABA combinations. 
Spirometry and peak expiratory flow devices were available in 24.4–29.4% and 6.7–53.6% respectively. Affordability 
of SABA and ICS varied greatly, ranging from < 2 to 107 days’ wages while ICS–LABA combinations, SAMA and oral 
theophylline plus leukotriene receptor antagonists cost 6.4–17.1, 13.7 and 6.9 days’ wages respectively.
Conclusion: Availability and affordability of medicines and diagnostics recommended for the management of 
asthma and COPD is a big challenge in SSA. Research about this subject in this region is still limited. More robustly 
performed studies are required to further understand the magnitude of inequity in access to these medicines and 
diagnostic tests in SSA and also to formulate simple pragmatic solutions to address this challenge.
Keywords: Availability, Affordability, Essential medicines, Diagnostic tests, Asthma, Chronic obstructive pulmonary 
disorders, COPD, Sub-Saharan Africa, Africa
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Background
Burden of asthma and COPD: Globally and in sub‑Saharan 
Africa
The global burden of chronic respiratory disorders (CRD) 
particularly asthma and chronic obstructive pulmonary 
disease (COPD) continues to increase especially in 
low-and middle income countries (LMIC), posing a 
substantial public health threat [1]. The 2015 Global 
Burden of Diseases, Injuries and Risk Factors (GBD) 
study reported an increase in the prevalence of asthma 
and COPD by 12.6% and 44.2% respectively from 1990 
to 2015. This was associated with an increased rate of 
mortality due to COPD [2]. In 2015, 3.2 million people 
and 0.4 million people died from COPD and asthma 
worldwide respectively. This represents an 11.6% increase 
in COPD-related deaths and a 26.7% decrease in asthma-
related deaths when compared to estimates in 1990 [2]. 
The majority of these deaths were reported in LMIC. 
Smoking (both active and passive), ambient particulate 
matter, household pollution and occupational triggers 
were identified as the key risk factors and contributors to 
DALYS for both asthma and COPD [2].
Increasing trends of morbidity due to asthma and 
COPD have also been reported in sub-Saharan Africa 
(SSA). Regarding the prevalence of asthma in Africa, 
a systematic review by Adeloye et  al. [3] of 45 relevant 
studies published between 1990 and 2012 estimated 
about 74.4 million, 94.8 million and 119.3 million asthma 
cases in the total population in 1990, 2000 and 2010 
respectively. A higher crude prevalence of asthma was 
noted in the urban areas compared to the rural areas.
A systematic review conducted in 2011 by Finney 
et  al. [4] reported estimates of COPD to vary between 
4 and 25%. This data was obtained from 9 studies 
that were performed in 4 countries (Nigeria, South 
Africa, Malawi and Cape Verde). Only one study used 
a population based representative sampling approach. 
Another systematic review performed by Adeloye et  al. 
[5] in 2012 that included 13 eligible studies (5 of which 
were based on spirometry data) reported a prevalence 
of COPD of 13.4% using spirometric data and 4% using 
non spirometric data. The most recent community 
surveys that have been conducted between 2013 to-date 
to ascertain the burden of COPD in Cameroon, Malawi, 
Nigeria, Uganda and Tanzania have reported prevalence 
of 2.4%, 7.7%, 4.2%, 16.2% and 17.5% respectively [6–10].
To effectively address the public health concern that 
asthma and COPD pose in SSA, health systems should be 
well structured to prevent, diagnose early and optimally 
manage these conditions. Consistent availability of 
affordable medicines and diagnostic tests is a fundamental 
component in the management of asthma and COPD 
in clinical practice. The Global Initiative for Asthma 
(GINA) and Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) guidelines recommend the use 
of inhaled short acting beta agonists (SABA), inhaled 
short acting anti muscarinic agents (SAMA), inhaled 
long acting anti muscarinic agents (LAMA), inhaled long 
acting beta agonists (LABA) and LAMA combinations, 
inhaled corticosteroid (ICS)–LABA combinations, ICS 
monotherapies, oral methylxanthines, oral leukotriene 
receptor antagonists (LTRA), pneumococcal vaccination 
and phosphodiesterase-4 inhibitors as the mainstay 
pharmacological therapies in the management of asthma 
and COPD [11, 12].
Citing the evident increase in morbidity and mortality 
due to asthma and COPD in SSA, it is essential 
to document the current status of availability and 
affordability of these medicines and diagnostic tests 
recommended for management of asthma and COPD 
in SSA. This will help in the guiding the formulation 
and implementation of pragmatic solutions to address 
the challenges of poor availability and high cost of these 
medicines and diagnostic tests.
Availability and affordability of medicines and 
diagnostic tests recommended for the management of 
asthma and COPD in SSA has not been systematically 
studied to-date. We, therefore undertook a systematic 
review of relevant original studies performed between 
2000 and March 2018 that investigated availability and 
affordability of these medicines and diagnostic tests in 
SSA.
Methods
A comprehensive literature search of PubMed, Scopus 
and African Journal Online was performed for original 
research articles in English language performed between 
2000 and March 2018 with an objective of determining 
the scope of availability and affordability of key medicines 
and diagnostic tests recommended in the management 
of asthma and COPD in SSA. References of the selected 
original research articles and published review articles 
were further searched for additional original research 
articles. We also searched the first 1000 Google scholar 
searches for original research articles.
Studies included were original research articles that 
contained information about availability and affordability 
of any known important medicine and diagnostic test for 
the management of asthma and COPD, was conducted 
in SSA between 2000 and March 2018 and published in 
English language.
Availability of any medicine (s) or diagnostic test (s) 
was expressed as a percentage of health facilities where 
it was present at the time of the study. Affordability was 
expressed as the total number of days’ wages it would 
cost the lowest paid unskilled government worker to pay 
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for a diagnostic test or a months’ cost of the medicine. 
This information was documented precisely as reported 
in the eligible original research article.
The classes of medicines of interest were those 
belonging to these categories: inhaled SABA, SAMA, 
LAMA, ICS, SABA-SAMA combinations, LABA–
LAMA combinations, ICS–LABA combinations, oral 
methylxanthines and LTRA. Studies that also contained 
information about the availability and affordability of 
spacer devices were also included due to their role in 
drug delivery especially in young children and elderly 
patients. The diagnostic tests of interest were spirometry 
and peak expiratory flow devices.
The following search terms were used: access OR 
affordability OR pricing OR cost OR availability AND 
“essential medicines” OR drugs OR therapies OR 
medicines AND tests OR diagnostic OR imaging AND 
asthma OR “chronic obstructive pulmonary disease” 
OR COPD OR “chronic respiratory disorders” AND 
Africa. The titles and abstracts of all studies were initially 
assessed for eligibility. Full texts of those studies that 
initially met the inclusion criteria were obtained and 
screened by 2 independent reviewers (DK and RES) and 
then exported to Endnote citation manager. Three extra 
authors (RN, WW and BK) independently reviewed 
the selected original research articles for the eligibility 
and key information about study setting and design and 
information about availability and affordability using 
a data extraction form. We excluded original research 
articles published in other languages other than English, 
studies whose full texts could not be accessed for full 
analysis and review articles.
The methodological quality of the identified studies 
was assessed by 2 independent reviewers (DK and RES) 
using the Newcastle–Ottawa scale. A maximum score 
of 6 and 9 was used for the selected cross sectional and 
case–control and cohort studies respectively [13].
The PRISMA guidelines for the reporting of systematic 
reviews were followed (Table  1) [14]. This systematic 
review was registered in PROSPERO (registration 
number: CRD42018093391).
Results
A total of 796 published articles were identified after 
searching the 3 databases. Thirty-two duplicates were 
removed, leaving 764 articles. The titles and abstracts of 
764 articles were screened. Of these, 737 articles were 
excluded because they lacked the information of interest. 
Full texts of 27 articles were assessed for eligibility and 
only 6 articles met the inclusion criteria. Three papers 
were added after searching Google Scholar, references of 
the eligible original articles and published review articles, 
making a total of 9 eligible original research articles 
which were included in the systematic review [15–23] 
(Fig. 1—Flow diagram summarizing the identification of 
eligible articles).
Study characteristics and methodological quality
All eligible studies were cross sectional in nature. Six 
of the studies (67%) were performed in a single African 
country (Malawi, Uganda-2 different studies, Nigeria, 
Ghana, South Africa) [15–17, 19, 20, 23]. The rest were 
multi-country studies performed in both an African 
country and other LMIC outside Africa [18, 21, 22]. In 
these multi-country studies, only data reported from the 
African countries was obtained.
Only 1 study was assigned the maximum score of 6 
[16], with the rest scoring 5 (n = 2, 22.2%) [19, 20] and 
4 (n = 6, 66.7%) [15, 17, 18, 21–23] on methodological 
quality.
The eligible original studies included in the systematic 
review are summarised in Table 2.
Availability of essential medicines used in management 
of exacerbations of both asthma and COPD (inhaled SABA 
and SAMA monotherapy)
Inhaled SABA monotherapies
Six studies evaluated the availability of inhaled SABA 
(inhaled salbutamol) [16, 17, 19–22] which ranged from 
19.9% in one study performed in Uganda [20] to 100% in 
Eriteria [22]. Low rates of availability of inhaled SABA 
were reported in a multi-centre study of 8 SSA countries 
(14% and 47% in public and private sector respectively) 
[21], Benin (33.3%) [22] and Ghana (39.1%) [19]. 
Comparable rates of moderate availability were reported 
in another study in Uganda (75%) [16] and other studies 
performed in Sudan (71.4%) [22] and Nigeria (76.5%) 
[17].
Inhaled SAMA monotherapy
Availability of inhaled SAMA (ipratropium bromide) was 
documented to be very low, with levels of 0% in Benin 
and Eriteria [22], 2.9% in Nigeria [17], 4.5% in Ghana 
[19], 12.3% in Uganda [16] and 14.3% in Sudan [22].
Availability of medicines used in symptom control 
of both asthma and COPD (ICS, ICS–LABA combinations, 
low dose theophylline, LTRA and inhaled tiotropium 
(LAMA)
Ics
Availability of ICS reported by 7 studies [15–20, 22] 
ranged from 0% in a multicenter study of 7 SSA countries 
[18] and in another study performed in Malawi [15] to 
45.5% in Uganda [16]. Very low availability of ICS was 
noted in another study performed in Uganda (1.5%) 
[20], a multi-country study involving 3 SSA countries 
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Table 1 Prisma checklist for the systematic review
Section/topic # Checklist item Reported on page #
Title
Title 1 Identify the report as a systematic review, meta-analysis, or both 1
Abstract
Structured summary 2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number
2–3
Introduction
Rationale 3 Describe the rationale for the review in the context of what is already known 4
Objectives 4 Provide an explicit statement of questions being addressed with reference to participants, 
interventions, comparisons, outcomes, and study design (PICOS)
5
Methods
Protocol and registration 5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, 
if available, provide registration information including registration number
7
Eligibility criteria 6 Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics 
(e.g., years considered, language, publication status) used as criteria for eligibility, giving 
rationale
5–6
Information sources 7 Describe all information sources (e.g., databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched
5
Search 8 Present full electronic search strategy for at least one database, including any limits used, 
such that it could be repeated
6
Study selection 9 State the process for selecting studies (i.e., screening, eligibility, included in systematic 
review, and, if applicable, included in the meta-analysis)
6
Data collection process 10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators
5–6
Data items 11 List and define all variables for which data were sought (e.g., PICOS, funding sources) and 
any assumptions and simplifications made
5
Risk of bias in individual studies 12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis
Not applicable
Summary measures 13 State the principal summary measures (e.g., risk ratio, difference in means) Not applicable
Synthesis of results 14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g.,  I2) for each meta-analysis
Not applicable
Risk of bias across studies 15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies)
Not applicable
Additional analyses 16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified
Not applicable
Results
Study selection 17 Give numbers of studies screened, assessed for eligibility, and included in the review, with 
reasons for exclusions at each stage, ideally with a flow diagram
7
Study characteristics 18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations
7–11
Risk of bias within studies 19 Present data on risk of bias of each study and, if available, any outcome level assessment 
(see item 12)
Not applicable
Results of individual studies 20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 
ideally with a forest plot
Not applicable
Synthesis of results 21 Present results of each meta-analysis done, including confidence intervals and measures 
of consistency
Not applicable
Risk of bias across studies 22 Present results of any assessment of risk of bias across studies (see item 15) Not applicable
Additional analysis 23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see item 16])
Not applicable
Discussion
Summary of evidence 24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy 
makers)
11–13
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(Benin-16.7%, Sudan-21.4% and Eriteria-33.3%) [22], 
Ghana (17.4%) [19], 23.5% (Nigeria) [17] and the private 
sector in Malawi (38%) [15].
Inhaled ICS–LABA combinations
Only 2 studies performed in Uganda [16] and Nigeria 
[17] assessed availability of ICS–LABA combinations; 
documenting comparable low rates of 46.9% and 50% 
respectively.
Oral low dose theophylline and LTRA 
Varying levels of availability of oral theophylline and 
LTRA were reported by 2 studies [16, 17]. In a study 
performed in Uganda, availability of oral theophylline 
and LTRA was 16.9% and 60.8% respectively [16] 
compared to 76.5% and 5.9% respectively in a study 
performed in Nigeria [17].
Inhaled LAMA (tiotropium)
Only 1 study investigated availability of inhaled 
tiotropium, reporting its absence in all health facilities 
surveyed [16].
Availability of medicines used in symptom control 
of COPD only (inhaled LABA monotherapy, SABA–SAMA 
combinations and LAMA and LABA combinations)
Availability of all the above medicines was studied 
by only 1 study, documenting comparable very low 
levels of availability of inhaled LABA monotherapies 
and SABA–SAMA combinations of 10% and 10.8% 
respectively. No surveyed health facility had any 
inhaled LABA–LAMA combination [16].
No study investigated the availability of LABA–
LAMA–ICS triple combinations, pneumococcal 
vaccines and phosphodiesterase 4 inhibitors which are 
essential medicines in the management of COPD.
Spacers
Due to the important role of spacers in drug delivery in 
the management of asthma and COPD in children and 
elderly patients, we also included information about 
their availability from 4 studies [16, 17, 19, 23]. With 
the exception of a study performed in South Africa 
where spacers were available in 72.9% of the surveyed 
46 primary healthcare facilities, the rest of the studies 
reported very low levels of availability of 0% in Ghana 
[19], 18.5% and 19.2% for adult and paediatric spacers 
respectively in Uganda [16] and 20.6% in Nigeria [17].
Availability of diagnostic tests for asthma and COPD
Only 4 studies contained findings about the availability 
of the diagnostic tests [16, 17, 19, 23]. Availability of 
peak expiratory flow devices was reported about in 
all the 4 studies (6.7% in Uganda, 13% in Ghana, 38% 
in Nigeria and 53.6% in South Africa). Availability of 
Table 1 (continued)
Section/topic # Checklist item Reported on page #
Limitations 25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., 
incomplete retrieval of identified research, reporting bias)
13
Conclusions 26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research
14
Funding
Funding 27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review
15
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA 
Statement. PLoS Med 6(7): e1000097
Records identified through 
database searching 
(n =796)
Additional records identified 
through other sources 
(n = 3)
Records after duplicates removed 
(n = 767)
Records screened 
(n = 767)
Records excluded 
(n =737)
Full-text articles 
assessed for eligibility 
(n = 30)
Full-text articles 
excluded 
(n = 21)
Studies included in 
qualitative synthesis 
(n = 9)
Fig. 1 Flow diagram for the systematic review
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spirometry was reported only by studies performed in 
Uganda (24.4%) [16] and Nigeria (29.4%) [17].
Affordability of medicines used in management 
of exacerbations of both asthma and COPD (inhaled SABA 
and SAMA monotherapies)
Inhaled SABA (salbutamol)
In a multi-centre study by Babar et al. [18] that included 
22 countries in SSA, the lowest priced generic (LPG) 
inhaled salbutamol cost < 2  days’ wages in 8 countries 
(Burkina Faso, Democratic Republic of Congo, Kenya, 
South Africa, Tanzania, Uganda, Zambia and Zimbabwe) 
and ≥ 2  days’ wages in 10 countries (Benin, Burundi, 
Cameroon, Ethiopia, Republic of Guinea, Madagascar, 
Malawi, Mali, Mozambique and Togo). Another multi-
centre study that included information from 8 countries 
in SSA reported the lowest priced generic (LPG) 
salbutamol inhaler to cost a mean of 1.6  days’ wages 
and 2.5  days’ wages in the public and private sector 
respectively. The innovator brand of salbutamol inhaler 
cost a mean of 4.4 days’ wages [21]. In another study done 
in Uganda, the LPG salbutamol inhaler cost 2.2  days’ 
wages [16].
Inhaled SAMA monotherapy (ipratropium)
The LPG SAMA (inhaled ipratropium) as reported by 
only 1 study cost 13.7 and 10.7 days’ wages for the 20 µg 
and 40 µg respectively [16].
Affordability of medicines used in symptom control 
of both asthma and COPD (ICS, ICS–LABA combinations, 
low dose theophylline, LTRA and inhaled LAMA)
Ics
A disparity in the affordability of generic and innovator 
ICS was observed in the study by Babar et  al. [18] that 
included information from 21 countries in SSA. The 
LPG beclometasone cost < 2  days’ wages in Kenya, 
South Africa, Uganda and Zambia and ≥ 2  days’ wages 
in Ethiopia, Madagascar, Malawi, Sudan and Zimbabwe. 
The cost of innovator budesonide was 48  days’ wages, 
51  days’ wages and 107  days’ wages in Burkina Faso, 
Mozambique and Republic of Guinea respectively. In 
Uganda, the LPG inhaled beclometasone, fluticasone 
propionate and budesonide cost 5.3  days’ wages and 
8 days’ wages respectively [16].
ICS–LABA combinations, SAMA–SABA combinations, low 
dose theophylline and LTRA 
Only 1 study contained information about the 
affordability of the above medicines [16]. Regarding 
ICS–LABA combinations, the reported cost of the 
LPG formoterol/beclometasone, salmeterol/fluticasone 
propionate and formoterol–budesonide was 6.4  days’ 
wages, 10.2 days’ wages and 17.1 days’ wages respectively. 
Inhaled SAMA–SABA (ipratropium–salbutamol 
combination) cost 10.7 days’ wages while oral LTRA and 
low dose theophylline both cost 6.9  days’ wages. Adult 
and paediatric spacers cost 12.9 and 7.5  days’ wages 
respectively [16].
Affordability of diagnostic tests of asthma and COPD
One study evaluated affordability of spirometry which 
cost up to 27.8 days’ wages [16].
Discussion
To our knowledge, this systematic review provides 
the first comprehensive assessment of availability and 
affordability of internationally recommended medicines 
and diagnostic tests in management of asthma and 
COPD in SSA. It also evidently demonstrates that studies 
investigating this key area in SSA are still limited and 
availability of affordable medicines and diagnostic tests 
still remains a substantial challenge in clinical practice in 
the region.
We noted considerable heterogeneity in the study 
results and health facilities surveyed. Poor availability was 
widely noted with SAMA, SAMA–SABA combinations, 
ICS, LAMA, LAMA–LABA combinations and diagnostic 
tests (spirometry and peak expiratory flow devices). The 
paucity of studies investigating access to LAMA and 
LAMA–LABA combinations, which are vital medicines 
in reducing COPD symptoms and future exacerbations is 
also revealing. This poor access to medicines for asthma 
and COPD has been highlighted in SSA and other LMIC 
and it carries substantial public health implications 
[24–27]. Availability of SABA (salbutamol inhaler) and 
LABA–ICS combination was > 70% in Uganda, Nigeria, 
Sudan and Eriteria [16, 17, 22] and > 45% in Uganda and 
Nigeria [16, 17]. The fairly good availability could explain 
the frequent use of SABA that has been described in 
patients with asthma and COPD in clinical practice.
Poor access to spirometry as a cornerstone for diagnosis 
and assessment of treatment response in patients 
with asthma and COPD as noted by this systematic 
review still remains a challenge. The poor availability of 
spirometry in health facilities and inadequate proficiency 
in interpretation of spirometric readings by healthcare 
workers in clinical practice has been widely documented 
as an impediment to optimal management of asthma and 
COPD in SSA [26–28]. The absence of adequate numbers 
of skilled personnel to perform spirometry and interpret 
its findings could also partly explain its low availability in 
SSA.
A dearth of studies about affordability of the medicines 
and diagnostic tests for asthma and COPD in SSA is 
also of great concern. The majority of the medicines 
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(controller therapies) especially in the private sector and 
innovator brands remain unaffordable for most patients 
in SSA.
Several reasons could explain the poor availability 
and high costs of the majority of the medicines and 
diagnostic tests in SSA. There exists a knowledge-
practice gap among healthcare practitioners in SSA 
resulting into patterns of clinical practice that are not 
in conformity with international treatment guidelines 
[27, 29]. Low prescribing rates of these medicines by 
healthcare practitioners directly or indirectly influence 
their availability both in the public and private sector. 
Exclusion of these medicines from the national essential 
medicine lists (EML) and treatment guidelines could 
also explain the poor availability in SSA. One survey 
that investigated the number of asthma and COPD 
essential medicines on the national EML of 32 LMIC 
(including some countries in SSA) noted that the median 
number of essential medicines was 7, with a range of 
0–22. Notably, no African country included LABA to 
their national EML. Few low income countries (LIC) 
included inhaled anti cholinergic agents (20%). None of 
the LIC included therapies recommended in step 4 and 5 
of asthma management by the GINA guidelines. Only a 
third of them included at least 1 medicine recommended 
in the step 2 and 3 of COPD management by the GOLD 
guidelines [30].
The high cost of the medicines and diagnostic tests in 
SSA could be explained by lack of local price regulatory 
frameworks or legislation, absence or poor access to 
national health insurance schemes that can provide 
the medicines at subsided fees, low scale of local 
pharmaceutical production of generic medicines and 
absence of public and private co-financing initiatives to 
reduce costs of drugs.
Strengths and limitations of the systematic review
One significant strength of this systematic review is being 
the first review to offer comprehensive information about 
the extent of availability and affordability of medicines 
and diagnostic tests of asthma and COPD in SSA. Despite 
this, some of the limitations are heterogeneity of the 
study findings and health facilities surveyed and the low 
methodological quality of the eligible original studies.
Conclusion
A better understanding of the magnitude and reasons 
to explain the challenge of poor availability and 
high cost of these medicines and diagnostic tests in 
SSA is important to guide better implementation of 
pragmatic solutions and guidelines. Poor availability 
and unaffordability of medicines and diagnostic tests 
recommended for the management of asthma and 
COPD in SSA could be addressed through increasing 
awareness about the burden of both conditions and their 
optimal management among healthcare practitioners, 
improving local manufacturing of cheap good quality 
generic medicines, updating national EML and treatment 
guidelines, improving supply chain and forecast and 
sustained and equitable government financing of health 
budgets. Implementation of health policies like national 
health insurance schemes, regulation of local retail prices 
of chronic diseases and introduction of preferential 
registration procedures for locally manufactured generic 
drugs by drug regulatory institutions can help address 
the challenge of high costs of medicines of asthma and 
COPD in SSA.
Due to differences in economic status of countries in 
SSA, more robust country-specific large studies about 
access to affordable essential medicines and diagnostic 
tests are needed to further appreciate the magnitude of 
this public health problem in this region.
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